Development PipelineEnfortumab vedotin

an investigational antibody-drug conjugate directed to Nectin-4

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

EV-302/KEYNOTE-A39: Locally advanced or metastatic urothelial cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

KEYNOTE-905/EV-303: Cisplatin-ineligible/decline cisplatin muscle-invasive bladder cancer

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

KEYNOTE-B15/EV-304: Cisplatin-eligible muscle-invasive bladder cancer

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-103/KEYNOTE-869: Urothelial cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-202: Locally advanced or metastatic solid tumors

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

EV-104: BCG-unresponsive non-muscle-invasive bladder cancer

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of enfortumab vedotin and ongoing clinical trials

Detailed information about enfortumab vedotin clinical trials

Related Videos

Enfortumab Vedotin Proposed Mechanism of Action